• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Methylphenidate Improves Mood and Boredom in Children with ADHD

Methylphenidate Improves Mood and Boredom in Children with ADHD

March 24, 2022
Pavan Madan, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Golubchik P et al, J Child Adolesc Psychopharmacol 2021;31(4):310–314


TYPE OF STUDY: Open label, ­uncontrolled


We are always looking for new angles to understand the conditions we treat. ADHD leads to significant academic and social impairments and is highly comorbid with depression and “boredom.” This study examines these associations using the Test of Variables of Attention (TOVA) to see whether methylphenidate (MPH) can help symptoms of depression and boredom in addition to ADHD symptoms.


Researchers enrolled 33 children (24 boys and 9 girls) aged 7–18 years with ADHD and looked at baseline and three-month post-MPH assessments using the parent-rated ADHD Rating Scale (ADHD-RS), the Short Boredom Proneness Scale (SBPS), and the Children’s Depression Inventory (CDI-total and its CDI-AS academic and social function subscale). TOVA was administered only at baseline and assessed omission errors, commission errors, and reaction time. MPH was dosed at 10–54 mg based on efficacy and tolerance.


The study found that higher severity of ADHD, depression, and boredom proneness led to worse reaction time (RT) and RT variability on TOVA. Youths with ADHD and low mood had worse attention span than those without low mood. Moreover, MPH treatment was associated with a significant improvement in not only the core ADHD symptoms, but also in academic and social function (CDI-AS) as well as boredom levels.


These results are limited by the study’s open-label design, its small sample size, the lack of TOVA after MPH, and the inability in this kind of study to calculate an effect size.


CCPR’s Take: Depression and boredom are part of cognitive dysfunction in ADHD, and the role of boredom deserves more investigation. Look for and track these symptoms in patients with ADHD. While more studies are always needed, MPH may be effective beyond core ADHD symptoms of inattention and hyperactivity-impulsivity and help associated depression and boredom.

Child Psychiatry
KEYWORDS adhd boredom depression methylphenidate mood
Pavan Madan, MD.

The Evidence Base for Polypharmacy in ADHD

More from this author
www.thecarlatreport.com
Issue Date: March 24, 2022
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - ADHD in Children and Adolescents, CCPR, April/May/June 2022
Note From the Editor-in-Chief
The Evidence Base for Polypharmacy in ADHD
Methylphenidate Improves Mood and Boredom in Children with ADHD
Talking with Parents About Stimulant Treatment
Treating Anxiety Disorders in Children: The New AACAP Clinical Practice Guideline
Practical Issues with Prescribing ADHD Meds
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.